Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Premenstrual Syndrome Treatment Market Report by Drug Type (Analgesics, Antidepressants, Oral Contraceptives and Ovarian Suppression Agents, and Others), Type (Prescription, Over-the-Counter), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032
Report Format: PDF+Excel | Report ID: SR112024A4284
Buy Now
Market Overview:
The global premenstrual syndrome treatment market size reached US$ 1,397.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,890.8 Million by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032.
|
Report Attribute
|
Key Statistics
|
|---|---|
|
Base Year
|
2023
|
|
Forecast Years
|
2024-2032
|
|
Historical Years
|
2018-2023
|
|
Market Size in 2023
|
US$ 1,397.0 Million |
|
Market Forecast in 2032
|
US$ 1,890.8 Million |
| Market Growth Rate 2024-2032 | 3.3% |
Premenstrual syndrome (PMS) treatment refers to the therapeutic processes utilized for minimizing emotional, physical and psychological symptoms, such as bloating, breast tenderness, body pain, fatigue, mood fluctuations and anxiety, in women. PMS is commonly observed at the end of the luteal phase and dissipates with menstruation or shortly after. The treatment involves the use of antidepressants, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, ovarian suppression agents and hormonal contraceptives. These drugs are usually available over the counter (OTC) or are prescribed by a doctor. Novel PMS treatment drugs, such as topical gels, creams, capsules and suppositories, are manufactured using cannabidiol extracts for the management of mood imbalances, minimizing uterine cramps and facilitating muscle relaxation.
Premenstrual Syndrome Treatment Market Trends:
The increasing prevalence of PMS and premenstrual dysphoric disorder (PMDD) across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the female working population. Moreover, rising awareness among the masses regarding available treatment alternatives for PMS and other related disorders is providing a thrust to the market growth. Pharmaceutical manufacturers are launching medications that have minimal side effects and aid in maintaining the appropriate pH balance in the body. Additionally, the widespread adoption of nutritional supplements manufactured using plant-based sources to provide relief from PMS is acting as another growth-inducing factor. These supplements contain the recommended amount of nutrients, such as calcium, magnesium, potassium and proteins, that aid in reducing fatigue and easing anxiety and depression. Healthcare organizations are also developing smartphone applications that periodically record physiological and emotional changes occurring in the body and send notification alerts as medication reminders. Other factors, including rising healthcare expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global premenstrual syndrome treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug type, type and distribution channel.
Breakup by Drug Type:
- Analgesics
- Antidepressants
- Oral Contraceptives and Ovarian Suppression Agents
- Others
Breakup by Type:
- Prescription
- Over-the-Counter
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Units | US$ Million |
| Segment Coverage | Drug Type, Type, Distribution Channel, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered | AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global premenstrual syndrome treatment market was valued at US$ 1,397.0 Million in 2023.
We expect the global premenstrual syndrome treatment market to exhibit a CAGR of 3.3% during 2024-2032.
The rising demand for premenstrual syndrome treatment, as it aids in minimizing emotional, physical, and psychological symptoms, such as bloating, breast tenderness, body pain, fatigue, etc., in women, is primarily driving the global premenstrual syndrome treatment market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective premenstrual syndrome treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals or medical equipment.
Based on the drug type, the global premenstrual syndrome treatment market can be segmented into analgesics, antidepressants, oral contraceptives and ovarian suppression agents, and others. Currently, analgesics hold the majority of the total market share.
Based on the type, the global premenstrual syndrome treatment market has been divided into prescription and over-the-counter, where over-the-counter drugs currently exhibit a clear dominance in the market.
Based on the distribution channel, the global premenstrual syndrome treatment market can be categorized into hospital pharmacies, drug stores and retail pharmacies, and online stores. Currently, drug stores and retail pharmacies account for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global premenstrual syndrome treatment market include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., and SHIONOGI & Co. Ltd.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More